Visitors Now:
Total Visits:
Total Stories:
Profile image
Story Views

Now:
Last Hour:
Last 24 Hours:
Total:

Bipolar Disorder Therapeutic Industry Pipeline Review H2 2016, Drug Profile and Major Key Players Analysis

Wednesday, November 30, 2016 3:09
% of readers think this story is Fact. Add your two cents.

(Before It's News)

Bipolar Disorder Pipeline Review, H2 2016, latest research study provides in depth analysis on Cellular Tumor Antigen P53 (Tumor Suppressor P53 or Antigen NY-CO-13) targeted pipeline therapeutics.

Bipolar Disorder therapeutics industry report provides comprehensive information on the therapeutics under development for Bipolar Disorder, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Bipolar Disorder and features dormant and discontinued projects.

Bipolar disorder was formerly called manic depression. It is a form of major affective disorder, or mood disorder, defined by manic or hypomanic episodes. Symptoms include decreased appetite and/or weight loss, or overeating and weight gain, fatigue, decreased energy, being slowed down, insomnia, early-morning awakening, or oversleeping, restlessness and irritability. The predisposing factors include age, stress and family history. Treatment includes anticonvulsants, antipsychotics and antidepressants.

Browse more detail information about Bipolar Disorder market report at: http://www.absolutereports.com/bipolar-disorder-manic-depression-pipeline-review-h2-2016-10435014

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
 

Key players in Bipolar Disorder – Pipeline Review, H2 2016:

  • Aequus Pharmaceuticals Inc.
  • Amorsa Therapeutics Inc.
  • AstraZeneca Plc
  • Biogen Inc
  • Delpor, Inc.
  • Intas Pharmaceuticals Ltd.
  • Intra-Cellular Therapies, Inc.
  • Johnson & Johnson
  • KemPharm, Inc.
  • Mapi Pharma Ltd.
  • Navya Biologicals Pvt Ltd
     

Get a PDF Sample of Bipolar Disorder Market Research Report at: http://www.absolutereports.com/enquiry/request-sample/10435014

Drug Profiles of Included in Bipolar Disorder Therapeutics Development Market Report

  • (cycloserine + lurasidone hydrochloride)
  • aripiprazole CR
  • aripiprazole ER
  • CB-2803
     

And other drug profiles
Have any query? ask our expert @
http://www.absolutereports.com/enquiry/pre-order-enquiry/10435014

Key Topics Covered:
1.Introduction
2.Bipolar Disorder Overview
3.Bipolar Disorder Therapeutics Development
4.Pipeline Products for Bipolar Disorder – Overview
5.Pipeline Products for Bipolar Disorder – Comparative Analysis
6.Bipolar Disorder – Therapeutics under Development by Companies
7.Bipolar Disorder – Therapeutics under Investigation by Universities/Institutes
8.Bipolar Disorder Products Glance
9.Late Stage Products
10.Clinical Stage Products
11.Early Stage Products
12.Bipolar Disorder – Products under Development by Companies
13.Bipolar Disorder – Products under Investigation by Universities/Institutes
14.Bipolar Disorder – Companies Involved in Therapeutics Development
15.Bipolar Disorder Drug Profiles
16.Bipolar Disorder Dormant Projects
17.Bipolar Disorder Discontinued Products
18.Bipolar Disorder Featured News & Press Releases

Oct 27, 2016: Sunovion Announces Positive Clinical Study Results for Latuda (lurasidone HCl) in Adolescents with Schizophrenia 108

Oct 18, 2016: NeuroRx Solidifies Intellectual Property Position Receives Notice of Allowance by US Patent Office 109

Sep 16, 2016: Sunovion to Present Data on Latuda (lurasidone) at the 29th European College of Neuropsychopharmacology (ECNP) Congress 110

Aug 09, 2016: Astellas Submits New Drug Application for Extended-Release Tablets of Quetiapine Fumarate in Japan 111

Jun 01, 2016: NeuroRx Awarded First Prize in Annual Israel BIOMED Startup Competition 111

May 23, 2016: Sunovion Announces Publication of Data Evaluating the Long-Term Safety and Tolerability of Latuda (lurasidone HCl) in the Treatment of Bipolar Depression 112

May 12, 2016: Sunovion to Present Data on Latuda (lurasidone HCl) at the 169th Annual Meeting of the American Psychiatric Association 113

Feb 25, 2016: Intra-Cellular Therapies Provides Product Update 114
And Continue…

Get Discount on Bipolar Disorder Market Research Report at: http://www.absolutereports.com/enquiry/request-discount/10435014

List of Tables

  • Number of Products under Development for Bipolar Disorder (Manic Depression), H2 2016
  • Number of Products under Development for Bipolar Disorder (Manic Depression) – Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Products under Development by Companies, H2 2016 (Contd..1)
  • Products under Investigation by Universities/Institutes, H2 2016

 

List of Figures

  • Number of Products under Development for Bipolar Disorder (Manic Depression), H2 2016 11
  • Number of Products under Development for Bipolar Disorder (Manic Depression) – Comparative Analysis, H2 2016 12
  • Number of Products under Development by Companies, H2 2016 13
  • Number of Products under Investigation by Universities/Institutes, H2 2016 15
  • Comparative Analysis by Late Stage Development, H2 2016 16
  • Comparative Analysis by Clinical Stage Development, H2 2016 17
  • Comparative Analysis by Early Stage Products, H2 2016 18
  • Assessment by Monotherapy Products, H2 2016 42
  • Number of Products by Top 10 Targets, H2 2016 44
  • Number of Products by Stage and Top 10 Targets, H2 2016 44
  • Number of Products by Top 10 Mechanism of Actions, H2 2016 46
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 46
  • Number of Products by Routes of Administration, H2 2016 48
  • Number of Products by Stage and Routes of Administration, H2 2016 48
  • Number of Products by Molecule Types, H2 2016 50

Number of Products by Stage and Molecule Types, H2 2016 50
 

Report abuse

Comments

Your Comments
Question   Razz  Sad   Evil  Exclaim  Smile  Redface  Biggrin  Surprised  Eek   Confused   Cool  LOL   Mad   Twisted  Rolleyes   Wink  Idea  Arrow  Neutral  Cry   Mr. Green

Top Stories
Recent Stories

Register

Newsletter

Email this story
Email this story

If you really want to ban this commenter, please write down the reason:

If you really want to disable all recommended stories, click on OK button. After that, you will be redirect to your options page.